Abstract:Background There is increasing interest in the role of brain-derived neurotrophic factor (BDNF) in the onset and course of schizophrenia, but there are conflicting reports about serum levels of BDNF in patients with schizophrenia. Aim Conduct a meta-analysis combining studies from China and other countries that have evaluated the relationship of serum BDNF levels to schizophrenia. Method We used Cochrane methodology and RevMan 5.1 software to identify and pool the results of studies. Electronic searches of western and Chinese registries and follow-up assessment of references located 268 potential articles. Twenty-five articles (20 in English and 5 in Chinese) published before December 2011 that used case-control methods, included patients with schizophrenia who had no concurrent disorders, and used ELISA technology to assess serum BDNF were included in the analysis. The main outcome was the pooled standardized mean difference (SMD) between cases and controls. The quality of the studies was independently assessed by two raters using the GRADE system. The heterogeneity, sensitivity and potential publication bias of the studies was evaluated using RevMan. Results The pooled sample included 1663 patients with schizophrenia and 1355 controls. Fifteen of the included studies were rated as ‘poor quality’ and 10 were rated as ‘very poor quality’. The results of the studies were quite heterogenous (I2=95%) but subgroup analyses found that the heterogeneity was not related to country of origin, sample size, age, gender, prior use of antipsychotic medication, or study quality. The pooled SMD (computed using a random-effect model because of study heterogeneity) was -0.74 (95% CI, -0.99∼-0.50; Z=5.99, p<0.001). Sensitivity analysis found that the result was stable and there was no evidence of publication bias. Conclusion Despite the robust statistical findings of lower serum BDNF in patients with schizophrenia than in controls, given the low quality of the available studies and the substantial heterogeneity between studies, the evidence of lower serum BDNF in patients with schizophrenia must be considered ‘weak’. The potential use of serum BDNF as a biomarker for schizophrenia must wait until higher-quality prospective studies that follow patients over time and that use uniform selection and monitoring procedures confirm these preliminary results.

Serum BDNF Levels and Weight Gain in Schizophrenic Patients on Long-Term Treatment with Antipsychotics

BDNF Levels and Genotype Are Associated with Antipsychotic-Induced Weight Gain in Patients with Chronic Schizophrenia

Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics.

Association of the BDNF Val66Met Polymorphism with BMI in Chronic Schizophrenic Patients and Healthy Controls

A control study of relationship between clinical features and serum levels of brain derivedneurotrophic factors in chronic schizophrenic patients

Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Schizophrenia: A Systematic Review

Influence of Olanzapine on Serum Prolactin Levels and BMI in Female Patients with Schizophrenia.

Association between the improvement in depressive symptoms and serum BDNF levels in drug-naive first episode patients with schizophrenia: A longitudinal follow-up

Sex differences in the association between serum BDNF and cognitive impairment in schizophrenia patients using various antipsychotics

Low BDNF is Associated with Cognitive Impairment in Chronic Patients with Schizophrenia

The Bidirectional Relationship Between Weight Gain and Cognitive Function in First-Episode Schizophrenia: A Longitudinal Study in China

Increased Serum Brain-Derived Neurotrophic Factor Levels Following Electroconvulsive Therapy or Antipsychotic Treatment in Patients with Schizophrenia.

Nicotine Dependence and Serum BDNF Levels in Male Patients with Schizophrenia

Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia

Diabetes mellitus, cognitive deficits and serum BDNF levels in chronic patients with schizophrenia: A case-control study

Interaction of BDNF with Cytokines in Chronic Schizophrenia.

Brain Derived Neurotrophic Factor (BDNF) Gene in Peripheral Blood Cells of Stable Schizophrenia

Blood Levels of Brain-Derived Neurotrophic Factor Correlate with Several Psychopathological Symptoms in Anorexia Nervosa Patients

The role of the gut microbiome in weight-gain in schizophrenia patients treated with atypical antipsychotics: Evidence based on altered composition and function in a cross-sectional study

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia.

Brain-derived neurotrophic factor, sex hormones and cognitive decline in male patients with schizophrenia receiving continuous antipsychotic therapy